Harvoni Treatment Porphyria Cutanea Tarda

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

March 4, 2022

Study Completion Date

March 4, 2022

Conditions
Porphyria Cutanea TardaHepatitis C
Interventions
DRUG

Harvoni

One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks

Trial Locations (3)

27157

Wake Forest University Health Sciences, Winston-Salem

77555

University of Texas Medical Branch, Galveston

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT03118674 - Harvoni Treatment Porphyria Cutanea Tarda | Biotech Hunter | Biotech Hunter